Navigation Links
Analysis Shows Novartis Drug TOBI® Associated With Reduced Mortality in Cystic Fibrosis Patients With Common Lung Infection
Date:10/21/2010

countries including the US and EU.

TOBI® (Tobramycin Inhalation Solution, USP) is a prescription inhaled medication for cystic fibrosis patients whose lungs contain bacteria called Pseudomonas aeruginosa. TOBI has not been studied in patients under six years of age, in those with a lung function outside of a certain range, or in those whose lungs contain bacteria called Burkholderia cepacia.

IMPORTANT SAFETY INFORMATION

If patients are allergic to antibiotics in the same family as TOBI (i.e., aminoglycosides), they should not take TOBI. They should tell their doctor before starting treatment if they have any history of hearing, kidney, balance, or muscle problems.

Patients taking TOBI may have temporary side effects like coughing or difficulty breathing. Some people taking TOBI experienced ringing in the ears, hearing loss, or changes in voice (hoarseness). Ringing in the ears may be a warning sign for hearing loss. If patients have ringing in the ears, changes in hearing, or dizziness, they should tell their doctor.

In studies, kidney damage was not seen in patients taking TOBI. However, antibiotics in the same family as TOBI have been linked to kidney damage.

If patients are pregnant, plan to become pregnant, or if they are breast-feeding, they should talk with their doctor before taking TOBI.

Some drugs may interact with TOBI. Patients should discuss all medications they are taking with your doctor.

Patients with cystic fibrosis can have many symptoms. Some of these may be related to their medications. They should tell their doctor if they have new or worsening symptoms.

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please visit www.pha
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Reportlinker Adds Global Top 10 Health Care Equipment Companies - Industry, Financial and SWOT Analysis
2. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
3. Reportlinker Adds Deep Analysis Report on Chinas Disinfectant Market 2010-2015
4. Transcept Pharmaceuticals to Host Conference Call to Discuss Preliminary Analysis of Intermezzo® Highway Driving Study
5. Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020
6. Reportlinker Adds Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020
7. Integrated Analysis Demonstrates That Denosumab Delays the Onset of Bone Complications Compared to Zometa®
8. ACD Wins $3 Million Grant From National Cancer Institute to Develop Its CTCscope™ System for Detection and Molecular Analysis of Circulating Tumor Cells
9. Boston Scientific Welcomes Publication of Analysis Demonstrating Long-Term Survival Benefit for ICD Therapy
10. Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports
11. Neuro Kinetics to Showcase Enhanced Control & Analysis Software at Otolaryngology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)...  Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... Phase II proof of concept clinical study investigating ... monotherapy in the treatment of chronic pruritus in ... and clinically meaningful improvement from baseline by tradipitant ... a 100mm unit Visual Analog Scale (VAS) for ...
(Date:3/4/2015)... Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the ... China, today announced its financial results for the fourth ... Quarter 2014 Financial Highlights , Total sales ... or 36.8% excluding the impact of foreign currency exchange ... the same quarter of 2013. , Gross profit ...
(Date:3/4/2015)... GSI Group Inc. (NASDAQ: GSIG ) (the ... of precision photonics and motion control components and subsystems ... today reported financial results for the fourth quarter and ... in this press release are GAAP measures from continuing ... of 2014, GSI generated revenue of $94.0 million, an ...
Breaking Medicine Technology:Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 2Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 3Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 4Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 5Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 6Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 2China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 3China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 4China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 5China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 6China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 7China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 8China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 9China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 10China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 11China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 12China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 13China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 14China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 15China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 16China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 17China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 18China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 19China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 20China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 21China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2014 22GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 2GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 3GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 4GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 5GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 6GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 7GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 8GSI Group Announces Financial Results for the Fourth Quarter and Full Year 2014 9
... human clinical data highlight safety profile of BSI-201 in ... subjects with advanced solid tumors ... a,privately held biopharmaceutical company developing novel cancer therapies,today announced that ... the 2008 American Society of Clinical Oncology annual,meeting in Chicago., ...
... ASCO Showed Acceptable Tolerability Profile, ... Low Incidence of Grade 3 and 4 Neuropathy, ... eribulin mesylate (E7389) demonstrated activity in a,heavily pretreated population ... to results of a multi-center Phase II clinical,trial. The ...
Cached Medicine Technology:BiPar Sciences Announces Clinical Data Presentations on Lead PARP Inhibitor, BSI-201, at 40th American Society of Clinical Oncology Annual Meeting 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 2Eribulin Mesylate Demonstrated Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Breast Cancer 3
(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... ) that allege the statin drug caused patients to ... the U.S. District Court, District of South Carolina. According ... be convened on March 26, 2015 at 10:00 a.m. ... directed to submit a Joint Status report to the ...
(Date:3/4/2015)... 04, 2015 Cook For Your Life ... teaches healthy cooking to people touched by cancer, is ... The program, run by founder Ann Ogden, will be ... Management. The unique partnership will expand the program from ... CFYL in 2007. After going through her own cancer ...
(Date:3/4/2015)... growing influence of movies, television, video games and the internet ... with the increasingly frantic lifestyle of modern parents, it can ... what kids are into these days. It seems that every ... , The same is also true for drugs and alcohol. ... talk about them, are constantly changing. These tips put a ...
(Date:3/4/2015)... 2015 Starting February 2015, Dr. Joseph ... procedures at their new location in Surrey. , In ... and Dr. Gabriel Chu also provide comprehensive ophthalmology services, ... named Fraser Valley Cataract and Laser (FVCL). This state ... College of Physicians and Surgeons of British Columbia. Fraser ...
(Date:3/4/2015)... (PRWEB) March 04, 2015 The print ... of The San Francisco Chronicle with a circulation of ... readers. Its digital component is distributed nationally through a ... top news sites and partner outlets. To explore the ... , Milorganite is composed of heat-dried microbes that ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:Drexel University and Cook for Your Life Team Up 2Health News:Drexel University and Cook for Your Life Team Up 3Health News:Drexel University and Cook for Your Life Team Up 4Health News:Drexel University and Cook for Your Life Team Up 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:King LASIK relocates to Surrey, British Columbia 2
... Awards Honor Unsung Heroes of Violence Prevention, ... history,with drug abuse, incarceration, and homelessness inspires her ... families. Orlando Ramos brings the,power of education and ... Billie Weiss conducts pioneering public-health research,that helps community- ...
... Nov. 12 Karen Ignagni, President,and CEO of America,s ... response to the new health care reform proposal,released by ... for health care reform. We commend Senator Baucus for,putting ... health,care challenges facing the nation. We look forward to ...
... The American Society of Plastic Surgical Nurses presented its ... a Rutgers College of Nursing faculty member, and her ... 1. , Rankin, clinical associate professor at The ... New Jersey, and her co-authors, Carrie Carretta, an advanced ...
... runs for Prime Minister or President should have an independent ... doctor on bmj.com today. , Lord David Owen, ... says that millions of people are affected by the decisions ... an obligation to the general public to ensure that their ...
... see doctors far more frequently, study finds , , WEDNESDAY, ... failure have many more doctor visits and take more ... , They based their conclusion on an analysis of ... of the beneficiaries was 70.7 years, while the average ...
... states plus Puerto Rico and District of Columbia get failing ... comes to premature birth rates, the United States rates a ... of Columbia get failing grades. , That,s the sobering conclusion ... Report Card , released Wednesday. Not a single state earned ...
Cached Medicine News:Health News:Three Community Leaders to Receive Foundation's 2008 California Peace Prize 2Health News:Three Community Leaders to Receive Foundation's 2008 California Peace Prize 3Health News:World leaders must be more open about their health 2Health News:Heart Failure Accounts for 37% of Medicare Spending 2Health News:U.S. Gets a 'D' for Preterm Birth Rates 2
With ten colors available, Spectrums line of Color-Coded Fiberoptic Light Cables makes it easy to track by department....
... gives you the exceptional performance you need at ... illumination, comfort and durability youd expect from headlights ... headlight. It features our thinnest cable and adjusts ... flexibility. Now when you reach for a headlight ...
... Sunnex Celestial Star™ light ... applications. The flexible design ... and positioning. The space-saving ... many facilities including emergency ...
The Next Generation in Single Lamp Technology, Advanced Optics & Reflector Design, Extended Depth of Field, 54" Useable Column of Light, High Intensity, Cool Beam Temperature...
Medicine Products: